Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia

Author(s):
Karen Sugden, Ph.D.\textsuperscript{1,2}; Avshalom Caspi, Ph.D.\textsuperscript{1,2,3,4}; Maxwell L. Elliott, Ph.D.\textsuperscript{1}; Kyle J. Bourassa, Ph.D.\textsuperscript{5}; Kartik Chamarti\textsuperscript{1}; David L. Corcoran, Ph.D.\textsuperscript{6}; Ahmad R. Hariri, Ph.D.\textsuperscript{1}; Renate M. Houts, Ph.D.\textsuperscript{1}; Meeraj Kothari, MPH\textsuperscript{7}; Stephen Kritchevsky, Ph.D.\textsuperscript{8}; George A. Kuchel, MD\textsuperscript{9}; Jonathan S. Mill, Ph.D.\textsuperscript{10}; Benjamin S. Williams, B.Sc.\textsuperscript{1,2}; Daniel W. Belsky, Ph.D.\textsuperscript{7,11}; Terrie E. Moffitt, Ph.D.\textsuperscript{1,2,3,4} on behalf of Alzheimer’s Disease Neuroimaging Initiative

Corresponding Author:
Karen Sugden, karen.sugden@duke.edu

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Equal Author Contribution:

Contributions:
Karen Sugden: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data
Avshalom Caspi: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data
Maxwell L. Elliott: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Kyle J. Bourassa: Drafting/revision of the manuscript for content, including medical writing for content
Kartik Chamarti: Drafting/revision of the manuscript for content, including medical writing for content
David L. Corcoran: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data
Ahmad R. Hariri: Drafting/revision of the manuscript for content, including medical writing for content
Renate M. Houts: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data
Meeraj Kothari: Analysis or interpretation of data
Stephen Kritchevsky: Drafting/revision of the manuscript for content, including medical writing for content
George A. Kuchel: Drafting/revision of the manuscript for content, including medical writing for content
Jonathan S. Mill: Drafting/revision of the manuscript for content, including medical writing for content
Benjamin S. Williams: Drafting/revision of the manuscript for content, including medical writing for content
Daniel W. Belsky: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Terrie E. Moffitt: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design

Figure Count:
3

Table Count:
4

Search Terms:

Acknowledgment:
We would like to thank the Northern California Institute for Research and Education, the Alzheimer’s Therapeutic Research Institute at the University of Southern California and the Laboratory for Neuro Imaging at the University of Southern California for curation, coordination, and dissemination of ADNI data. The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195,
HHSN2682015000011 and 75N92019D00031). Funding support for the Framingham Dementia Survival Information for All Cohorts dataset was provided by NIA grant R01-AG054076. This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI.

Study Funding:
This work was supported by the National Institute on Aging (R01AG032282, R01AG049789, F99 AG068432-01, R01AG061378, R01AG073207, and T32-AG000029), the UK Medical Research Council (MR/P005918/1), the Lafitte Foundation, the National Science Foundation (Graduate Research Fellowship no. NSF DGE-1644868), Russell Sage Foundation BioSS (1810-08987), and the North Carolina Biotechnology Center (2016-IDG-1013). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) supported by the National Institutes of Health (U01AG024904) and Department of Defense (W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CernePhar, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development, LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).

Disclosures:
K. Sugden; A. Caspi; D. L. Corcoran; D. W. Belsky; T. E. Moffitt are listed as inventors on a Duke University and University of Otago invention that is licensed to a commercial entity. The other authors report no relevant disclosures.

Preprint DOI:

Received Date:
2021-12-22

Accepted Date:
2022-05-13

Handling Editor Statement:
Submitted and externally peer reviewed. The handling editor was Linda Hershey, MD, PhD, FAAN.
Abstract

Background and Objectives. DNA methylation algorithms are increasingly used to estimate biological aging; however, how these proposed measures of whole-organism biological aging relate to aging in the brain is not known. We used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Framingham Heart Study (FHS) Offspring Cohort to test the association between blood-based DNA methylation measures of biological aging and cognitive impairment and dementia in older adults.

Methods. We tested three ‘generations’ of DNA methylation age algorithms (1st generation: Horvath and Hannum clocks; 2nd generation: PhenoAge and GrimAge; and 3rd generation: DunedinPACE, Dunedin Pace of Aging Calculated from the Epigenome) against the following measures of cognitive impairment in ADNI: clinical diagnosis of dementia and mild cognitive impairment; scores on AD/ADRD screening tests (Alzheimer’s Disease Assessment Scale; Mini-Mental State Examination; Montreal Cognitive Assessment); and scores on cognitive tests (Rey Auditory Verbal Learning Test; Logical Memory Test; Trail Making Test). In an independent replication in the FHS Offspring Cohort, we further tested the longitudinal association between the DNA methylation algorithms and risk of developing dementia.

Results. In ADNI (N = 649 individuals), the 1st generation (Horvath and Hannum DNA methylation age clocks) and the 2nd generation (PhenoAge and GrimAge) DNA methylation measures of aging were not consistently associated with measures of cognitive impairment in older adults. In contrast, a 3rd generation measure of biological aging, DunedinPACE, was associated with clinical diagnosis of Alzheimer’s Disease (beta[95%CI]=0.28[0.08-0.47]) and with poorer scores on AD/ADRD screening tests (beta[Robust SE]=-0.10[0.04] to 0.08[0.04]), and cognitive tests (beta[Robust SE]=-0.12[0.04] to 0.10[0.03]). The association between faster
pace of aging, as measured by DunedinPACE, and risk of developing dementia was confirmed in a longitudinal analysis of the FHS Offspring Cohort (N = 2,264 individuals, HR[95%CI] =1.27[1.07-1.49]).

**Discussion.** Third generation blood-based DNA methylation measures of aging could prove valuable for measuring differences between individuals in the rate at which they age, in their risk for cognitive decline, and for evaluating interventions to slow aging.

**Introduction**

Aging can be conceptualized as gradual and progressive deterioration in biological system integrity causing morbidity and disability. These changes, in turn, are thought to increase vulnerability to multiple age-related diseases, including dementias. Advances in both basic and applied aging research could be spurred by the availability of tools that can measure biological aging. Medical, behavioral, and social sciences need measures of biological aging in order to identify risk factors and mechanisms that accelerate aging and to use in studies of social groups that are thought to be aging at different rates. Applied science needs measures of biological aging in order to evaluate whether interventions succeed in slowing aging. Multiple companies are developing drug therapies that target aging biology, and several are being evaluated in human trials (clinicaltrials.gov). Behavior-change science is also working toward interventions to extend healthspan, including increasing physical activity, hypertension control, cognitive stimulation, dietary modification, and social engagement. Whether they are pharmaceutical or behavioral, interventions that aim to extend healthspan need to have a measure to evaluate whether or not aging has indeed been slowed. However, as of this writing, there is no widely accepted measure of biological aging. This article reports the association between
dementia, one of the most feared and costly diseases of aging, and five leading candidate measures of aging based on DNA methylation.

DNA methylation is an epigenetic mechanism by which specific points of the genome (CpGs) are chemically modified (methylated) and thereby affect gene regulation. Recent efforts to develop measures of aging have focused on blood DNA methylation because it is a biological substrate that is sensitive to age-related changes. Using machine learning, these measurement efforts involve developing algorithms to capture information about aging by using data about DNA methylation levels of multiple CpGs across the genome. These methylation algorithms have evolved rapidly. The first generation of methylation algorithms was trained on chronological age in samples ranging in age from children to older adults. These “clocks” identified methylation patterns that vary by chronological age. If a person’s score on such clocks is older than his/her actual age, it is inferred that s/he is biologically older. The first-generation algorithms include the “Hannum clock” and the “Horvath clock.” The second generation of methylation algorithms added measures of people’s current physiological status in order to identify methylation patterns that account for differences in current health and that predict mortality. These second-generation algorithms include PhenoAge and GrimAge. The DunedinPACE (Pace of Aging Calculated from the Epigenome) is a third-generation algorithm that was developed by first measuring people’s rate of physiological change over time and then identifying the methylation patterns that captured individual differences in their age-related decline. Specifically, it measured age-related change in 19 biomarkers among individuals of the same chronological age over a 20-year observation period and then identified methylation patterns at the end of the observation period that estimated how fast aging occurred during the
years leading up to the point of measurement. Thus, it is designed to capture methylation patterns reflecting individual differences in age-related decline.

These DNA methylation algorithms have been embraced by the research community as well as by private companies. But the literature evaluating them is fragmented. Although all of these algorithms purport to measure aging, they have surprisingly low agreement; articles often report promising findings from one (or more) DNA methylation algorithms, but often in different samples, and many algorithms show inconsistent associations with outcomes. Important validation steps are now being taken to rigorously evaluate multiple DNA methylation algorithms in the same study (e.g., in the Health and Retirement Survey). What has not been reported is an evaluation of multiple DNA methylation algorithms in the same study with the outcome of dementia.

Here we leverage data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to test associations of the leading measures from the three generations of DNA methylation algorithms with cognitive aging and dementia. We examined three sets of “gold standard” measurements in cognitive-aging research. First, we compared the DNA-methylation algorithms’ scores as a function of ADNI participants’ diagnoses: Cognitively Normal, Mild Cognitive Impairment (MCI), or Dementia. Second, we evaluated the algorithms in relation to three instruments that are used as cognitive screening tools for AD/ADRD: The Alzheimer’s Disease Assessment Scale (ADAS-Cog-13), the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA). Third, we evaluated the algorithms in relation to well-established tests of learning and memory (Rey Auditory Verbal Learning Test), episodic memory (Logical Memory Test), and executive function (Trail Making Test) that are known to decline with age. We then turned to a second independent sample, the
Framingham Heart Study (FHS) Offspring Cohort, to evaluate whether and which DNA methylation measures of biological aging could longitudinally predict risk of developing dementia.

**Methods**

**The ADNI DNA Methylation Sample**

Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The primary goal of ADNI has been to test whether magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Inclusion and exclusion criteria included: Hachinski Ischemic Score \(^{31} \leq 4\); Geriatric Depression Scale score \(^{32} < 6\); visual and auditory acuity adequate for neuropsychological testing; good general health with no diseases precluding enrollment; sixth grade education or work-history equivalent; no medical contraindications to MRI; no psychoactive medications that affect cognitive function; medications stable for 4 weeks prior to screening; and not enrolled in other trials or studies concurrently. \(^{33}\)Data were downloaded from the ADNI data repository (adni.loni.usc.edu) on June 3rd 2020.

**DNA Methylation Data**

DNA methylation was measured in DNA from whole blood using the Illumina Infinium HumanMethylationEPIC BeadChip Array and run at AbbVie. 649 ADNI participants had
methylation data. Participants varied on the number of repeat DNA methylation measurements they had; 83 had only a baseline measurement; 121 had 2 measurements (baseline plus 1 repeat, mean 14.5 months between measurements (SD=7.06); 407 had 3 measurements, mean 12.1 months between measurements (SD=1.5); 29 had 4, mean 10.4 months between measurements (SD=3.54); and 9 had 5, mean 12.52 months between measurements (SD=2.25). Samples were randomized using a modified incomplete-balanced-block design, whereby all samples from a participant were placed on the same chip, with remaining chip space occupied by age- and sex-matched samples. Participants from different diagnosis groups were placed on the same chip to avoid confounding.

DNA methylation data were subjected to QC by ADNI investigators prior to receipt. Samples with missing rate >1% at p < 0.05, poor SNP matching to the 65 SNP control probe locations, and uncertain sex were excluded. Filtered data were normalized using the ‘NormalizeMethylumiSet’ function in the \textit{R} package \textit{Methylumi}. Prior to normalization, replicate samples (test-retest of the same sample, \(N=198\)) were identified and removed from the dataset. Probes were removed if detection p-value was>0.05 in more than 10% of individuals (\(N=611\) probes).

A flowchart documenting the number of samples at each stage of data preparation is found in \textit{eFigure 1, Panel A}.

\textbf{Cognitive Assessments}

Data about diagnosis, cognitive impairment screening tests and cognitive function were extracted from data tables available in the ‘\textit{ADNIMERGE}’ package in \textit{R}, and then cross-matched to participants with available DNA methylation data. Measures are described below.
**Diagnosis.** Diagnosis was made by a study physician at time of assessment and categorized as “Cognitively Normal”, “Mild Cognitive Impairment” and “AD-dementia”.

**Clinical assessment.** The Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog-13) is a structured scale that evaluates memory, reasoning, language, orientation, ideational praxis and constructional praxis. Delayed Word Recall and Number Cancellation are included in addition to the eleven standard ADAS-Cog Items. The test is scored in terms of errors, ranging from 0 (best performance) to 85 (worse performance). The Mini-Mental State Exam (MMSE) is a screening instrument that evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. The MMSE is scored as the number of correctly completed items ranging from 0 (worse performance) to 30 (best performance). The Montreal Cognitive Assessment (MoCA) is designed to detect individuals at the MCI stage of cognitive dysfunction. The scale ranges from 0 (worse performance) to 30 (best performance).

**Cognitive function.** The Rey Auditory Verbal Learning Test is a list learning task which assesses learning and memory. On each of 5 learning trials, 15 unrelated nouns are presented orally at the rate of one word per second and immediate free recall of the words is elicited. Following a 30-minute delay filled with unrelated testing, free recall of the original 15-word list is elicited. Both immediate recall and the percent forgotten are used. The Logical Memory Test I and II (Delayed Paragraph Recall) is from the Wechsler Memory Scale-Revised (WMS-R). Free recall of one short story is elicited immediately after being read aloud to the participant and again after a thirty-minute delay. The total bits of information recalled after the delay interval (maximum score = 25) are analysed. The Trail Making Test: Part B consists of 25 circles, either numbered (1 through 13) or containing letters (A through L). Participants connect the circles
while alternating between numbers and letters (e.g., A to 1; 1 to B; B to 2; 2 to C). Time to complete (300 second maximum) is the primary measure of interest.

The Framingham Heart Study Offspring DNA Methylation Sample

The Framingham Heart Study tracks the development of cardiovascular disease in three generations of families recruited in Framingham, Massachusetts beginning in 1948\(^35\). We analyzed data from the second generation of study participants, who were recruited beginning in 1971. They are known as the Offspring Cohort\(^36\). To be included in the DNA methylation Study, participants must have attended the Framingham Offspring 8\(^{th}\) follow-up visit during 2005-2008 and have provided a buffy coat sample.

DNA Methylation Data

DNA methylation was measured in DNA samples from whole blood using Illumina 450k Arrays and run at the University of Minnesota and Johns Hopkins University (dbGaP phs000724.v9_p13).

Data were normalized using the ‘dasen’ method in the watermelon R package and subjected to downstream QC. Samples with missing rate >1\% at \(p < 0.01\), poor SNP matching to the 65 SNP control probe locations, and outliers by multi-dimensional scaling techniques were excluded. Probes with missing rate of >20\% at \(p < 0.01\) were also excluded. Additional information on DNA methylation, normalization, and quality control is available in Mendelson et al.(2017)\(^37\).
A flowchart documenting the number of samples at each stage of data preparation is found in **eFigure 1, Panel B**.

**Dementia diagnosis**

As previously published\(^38\)\(^-\)\(^40\), participants in this cohort have been assessed at each examination with the Mini–Mental State Examination (MMSE) and flagged for further examinations if a) they were identified as having possible cognitive impairment on the basis of screening assessments; or b) when subjective cognitive decline was reported by the participant or a family member; or c) on referral by a treating physician or by ancillary investigators of the Framingham Heart Study; or d) after review of outside medical records. All cases of possible cognitive decline and dementia were reviewed to determine presence of dementia, as well as dementia subtype and date of onset\(^39\).

Dementia ascertainment in our dataset extended through 2018 (dbGaP accession pht010750.v1.p13, dataset vr_demsurv_2018_a_1281s). Dementia status was determined for 2,468 participants. Of this group, \(N=2,264\) were alive and free of dementia at DNA methylation baseline. This analysis sample contributed a maximum of 14 years of follow-up time for dementia ascertainment, over which interval \(n=151\) (64 men and 87 women) developed dementia at an average age of 82 years (SD=6).

**DNA methylation Clock estimation**

In both ADNI and the FHS Offspring Cohort, we calculated four of the DNA methylation Age (DNAmAge) clocks (Horvath, Hannum, PhenoAge and GrimAge) using the online calculator found at https://dnamage.genetics.ucla.edu/new. The ‘normalization’ and ‘advanced
analysis in blood’ options were selected, and data were anonymized prior to upload. From the results file, we extracted the corresponding DNA methylation age calculations (DNAmAge, DNAmAgeHannum, DNAmPhenoAge, DNAmGrimAge) along with the estimates of white blood cell type abundance. DunedinPACE was calculated in R following the procedures described in Belsky et al.\textsuperscript{17}. To account for potential technical confounding introduced during DNA methylation measurement (e.g. differential reaction efficiency between batches of assays), values of the five algorithms were residualised for the DNA plate number. Finally, to derive estimates of DNA methylation age advancement, these values were further residualised for chronological age at the time of the DNA assessment.

**Statistical analysis**

All analyses were conducted in R, except for Cox proportional regression analyses in the FHS Offspring Cohort which were conducted in STATA. All regression models were adjusted for sex. To enable effect size comparisons, all age-residualized scores were standardized to Mean=0, SD=1 prior to analysis. In ADNI, we calculated Huber-White robust standard errors using the \texttt{plm} and \texttt{lmtest} packages in R to account for the fact that some individuals contribute more than one time point as described in the ‘\texttt{10.1371/journal.pmed.1002215}. In FHS, effect-sizes are reported as hazard ratios (HR) per SD increment of the aging measures estimated from Cox proportional hazard regression. To adjust means for sex, we calculated least-squares means with proportional weights in the \texttt{lsmeans} package in R. To account for technical variation, we also tested models adjusted for white blood cell abundance (Plasmablasts, +CD8pCD28nCD45RA-T cells, naïve CD8 T cells, CD4 T cells, Natural Killer cells, Monocytes
and Granulocytes). All analyses were performed in parallel by a second, independent researcher to confirm reproducibility.

**Standard Protocol Approvals, Registrations, and Patient Consents**

All research activities were approved by Institutional Review Boards (IRB) at the participating study sites. Participants provided written informed consent.

**Data Availability**

All data used in this report are publically available; access is granted after application approval from the relevant study’s research review committee (ADNI: http://adni.loni.usc.edu/data-samples/access-data/; FHS Offspring Cohort: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000724.v9.p13).
Results

DNA methylation measures of aging in ADNI

DNA methylation data were available for 649 individuals and 1,706 samples (mean(SD) age at first DNA collection=74.77(7.66), male=55.6%). Mean education of the 649 individuals was 16.22 years (SD=2.71), and the majority self-identified as White (N =636, 98.0%). Table 1 describes characteristics of participants in ADNI.

Table 2 contains descriptive data (mean, (SD) and range) about the five measures of DNA methylation aging. The Horvath, Hannum, PhenoAge, and GrimAge clocks are measured in units of chronological years, and DunedinPACE is measured in years of physiological decline per 1 chronological year. All DNA methylation measures of aging were associated with sex; males had older DNA methylation age on the clocks and faster DunedinPACE. All following analyses include sex as a covariate. Similarly, all DNA methylation measures of aging were correlated with chronological age, such that chronologically older individuals appeared to have older DNA methylation age on the clocks and faster DunedinPACE (ranging from $r=0.30$ for DunedinPACE to $r=0.85$ for GrimAge). Going forward we utilize measures of DNA methylation age advancement, derived by residualizing the measures described in Table 2 for participant age at the time of DNA data collection, rendering them uncorrelated with age. Figure 1 shows the correlations between the measures of DNA-methylation age-advancement. The measures were significantly intercorrelated; the largest correlations were observed between the first-generation clocks and PhenoAge ($r=0.45–0.56$) and between GrimAge and DunedinPACE ($r=0.47$); otherwise, correlations ranged from $r=0.14$ to $r=0.28$. 
Association between DNA methylation measures of aging and dementia diagnosis in ADNI

At each DNA data-collection point, ADNI participants were categorized into three diagnostic groups. Figure 2 shows the mean values of the five DNA methylation measures of aging for the three diagnostic groups: Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and Dementia (for comparison purposes, DNA-methylation age-advancement values have been standardized to Mean=0 and SD=1). The three diagnostic groups did not differ significantly from one another on first-generation clocks (Horvath and Hannum) or second-generation clocks (PhenoAge and GrimAge). In contrast, we observed an ordered association between diagnoses of CN, MCI, and Dementia for DunedinPACE: Individuals with a diagnosis of MCI (beta=0.19, 95% CI:0.03-0.34) and, to a greater extent, individuals with a diagnosis of Dementia (beta=0.28, 95% CI:0.08-0.47) had significantly faster DunedinPACE scores than CN individuals (see eTable 1 for details).

Association between DNA methylation measures of aging and cognitive function in ADNI

At each DNA collection, ADNI participants were given three cognitive screening tests: The ADAS-Cog-13, the MMSE, and the MoCA. Table 3, Panel A shows the associations between the five DNA-methylation measures of aging and scores on these three cognitive screening tests. Neither of the first generation DNA-methylation clocks nor GrimAge were associated with scores on the ADAS-Cog-13, MMSE or MoCA (beta=-0.03 to 0.03). In contrast, advanced PhenoAge and faster DunedinPACE scores were both associated with worse scores on ADAS-Cog-13 (beta=0.07 to 0.08) as well as MMSE and MoCA (beta=-0.06 to -0.10), indicating greater cognitive impairment.
ADNI participants were also administered a battery of cognitive function tests. Table 3, Panel B shows the associations between the five DNA methylation measures of aging and four measures of cognitive functioning: Rey Auditory Verbal Learning Test (both learning and memory), Logical Memory Test (episodic memory), and the Trail Making Test (executive function). Neither the first generation clocks (Horvath and Hannum) nor GrimAge were consistently associated with performance on these tests (beta=-0.05 to 0.01). In contrast, advanced PhenoAge and, to a greater extent, faster DunedinPACE scores were both associated with significantly worse learning (beta=-0.06 to -0.12), more forgetting (beta=0.06 to 0.10), and worse episodic memory (beta=-0.10 to -0.11) (Figure 3 and eFigure 2).

Sensitivity and secondary analyses

Associations reported here were robust in several sensitivity analyses (eTables 1-3). First, associations were robust to distributional assumptions. Both the dementia-screening tests and the cognitive function measures had distributions that deviated from normal. As such, we repeated all analyses comparing results with the ‘native’ (i.e., original) scores, log-transformed scores, and scores binned into quintiles. Regardless of how we handled the distributions, the results were comparable (eTable 2-3). Second, after controlling for abundance estimates of different types of white blood cells, associations between DunedinPACE and clinical diagnoses and cognitive function tests were smaller but remained statistically significant at the alpha=0.05 level (eTables 1 and 3), whereas those with the dementia-screening tests fell short of significance (eTable 2). Importantly, Pace of Aging, on which DunedinPACE was trained in an independent sample, includes longitudinal change in observed white blood cell abundance, making this an overcontrol. Finally, ApoE4 is known to be associated with dementia risk;
However, it was not associated with first-, second-, or third-generation DNA methylation measures of aging (eTable 4).

Association between DNA methylation measures of aging and dementia in the Framingham Heart Study (FHS) Offspring Cohort: Replication and extension

To replicate and extend the test of the association between DunedinPACE and dementia, we turned to the FHS Offspring cohort. This longitudinal analysis included \( N = 2,264 \) participants with a maximum of 14 years of follow-up time for dementia ascertainment. Over this time interval \( n = 151 \) (64 men and 87 women) developed dementia at an average age of 82 years (SD = 6).

Participants measured to have more advanced aging on the clocks and faster DunedinPACE at baseline were at increased risk of developing dementia over follow-up; the largest effect was for DunedinPACE (HR[95%CI] = 1.39[1.21-1.61]), followed by PhenoAge, GrimAge, and Horvath (Table 4). As with ADNI, sensitivity analyses controlling for white blood cell abundance estimates attenuated effect sizes; only DunedinPACE (HR[95%CI] = 1.27[1.07-1.49]) and the Horvath clock (HR[95%CI] = 1.21[1.08-1.36]) significantly predicted risk of dementia at \( p < 0.05 \) (Table 4 and eFigure 3).

Discussion

Aging increases risk for Alzheimer’s disease, related dementias and cognitive impairment. Moreover, the vast majority of cases occur later in life and for such individuals, unlike those with the less common familial AD, aging represents the largest risk factor for dementia. The potential to capture the individual dynamics that define the risk of cognitive decline attributable to biological aging is of great interest to gerontologists and clinicians alike.
In this report, using data from ADNI and the FHS Offspring Cohort, we compared associations between first-, second-, and third-generation DNA-methylation measures of aging and multiple measures of cognitive aging and dementia. When evaluated against clinical screening test scores, measures of cognitive functioning, and a clinical diagnosis of dementia, the third-generation DunedinPACE measure was more predictive than earlier generations of clocks. In ADNI, it was the only biological aging estimate to show consistent associations with every measure of cognitive impairment tested in the predicted direction of faster aging and more impairment. Moreover, faster DunedinPACE was associated with increased risk of developing future dementia in the FHS Offspring Cohort.

A DNA methylation algorithm that can assess biological aging should be robustly associated with cognitive dysfunction characteristic of AD/ADRD. First, we showed that individuals with a diagnosis of dementia and, to a lesser extent, mild cognitive impairment had faster DunedinPACE compared to individuals who were cognitively normal. This pattern was not observed for the first- and second-generation DNA methylation age-advancement clocks. Second, individuals who scored poorly on screening measures commonly used in memory clinics (ADAS-Cog-13, MMSE, MoCA) had older DNA-methylation age advancement (assessed via PhenoAge) and faster DunedinPACE. Third, individuals’ worse cognitive function was associated with older DNA methylation age advancement (assessed via PhenoAge) and faster DunedinPACE. It is important to note that the cognitive measures that we examined overlap to some extent; for example, the Logical Memory Test is used to derive AD diagnoses. However, we think it essential to present evidence from all of the cognitive measures because different studies often evaluate different cognitive measures, making it difficult to compare studies and reconcile inconsistencies.
Previous studies testing associations between DNA methylation clocks and late-life cognition and dementia have yielded equivocal and inconsistent evidence\textsuperscript{21, 44-46}. In contrast, the present study suggests that the newer generation DunedinPACE measure is consistently associated with multiple manifestations of age-related cognitive deficits. This is consistent with previously reported evidence that faster DunedinPACE is associated with greater cognitive decline during midlife\textsuperscript{17}. This consistency suggests that vulnerability to cognitive impairment that is the hallmark of risk for dementia can be captured by considering how fast a person is aging biologically compared to their age-peers. The finding that extremely fast DunedinPACE scores occur with dementia is consistent with the view that dementia is not part of normal aging.

Consistent with previous studies (e.g.\textsuperscript{17-19, 24, 47, 48}), the five tested DNA methylation measures of aging vary in the extent to which they are intercorrelated, and clocks in the same generation tend to be more highly correlated with one another. This suggests that although different DNA methylation measures of aging capture some common elements, they are also clearly distinct. First-generation clocks were trained to predict chronological age. This approach is based on the assumption that differences in DNA methylation between older and younger people represent biological processes of aging. Second-generation clocks were trained to predict mortality, using physiological variables as intermediates. This approach is based on the assumption that differences in DNA methylation between people with higher as compared to lower risk for mortality represent biological processes of aging. The third-generation DunedinPACE was trained to predict biological change between ages 26-45 years in a same-age cohort. This approach is based on the assumption that DNA-methylation differences between people experiencing slower as compared to more rapid decline in the function of multiple organ systems represent biological processes of aging. The evidence presented here suggests that
progressive generations of clocks may be more sensitive predictors of cognitive outcomes. Moreover, the association of DunedinPACE with dementia recommends midlife prevention if some patients’ course toward dementia begins in midlife.

There are caveats and limitations. First, despite robust associations between DunedinPACE and measures of cognitive aging, none of the currently available measures of DNA-methylation aging match clinically-validated risk markers of ADRD on strength-of-association. For example, within the ADNI participants analyzed in the present report, individuals with a diagnosis of dementia were 12 times more likely to carry 2 \( APOE \varepsilon 4 \) alleles than individuals who were cognitively normal (CN), an effect size of a 0.94 SD-unit difference between dementia vs CN. To put the effect size for the DunedinPACE comparison between dementia vs CN in perspective, it yielded a 0.28 SD-unit difference. Second, the majority of participants are white because of the lack of ethnic diversity of the participants enrolled in ADNI and Framingham. Initial evidence shows that an earlier version of a methylation Pace of Aging algorithm, DunedinPoAm, is associated with poorer physical health among both Black and White participants, but more research is needed on this front. Third, we were able to report only cross-sectional associations between DNA-methylation measures of aging and cognitive impairment and AD in ADNI because the number transitioning to a new diagnosis was too small for statistical power among ADNI participants who had methylation data. To overcome this limitation, we extended our analysis to the larger FHS Offspring Cohort and found that DunedinPACE was associated prospectively with future risk of developing dementia. Fourth, this study reports initial replicated evidence that DunedinPACE derived in midlife signals dementia risk in late life, but life-course longitudinal studies should evaluate potential causal pathways including early-life age accelerators (e.g., low socioeconomic status, low education,
smoking) and potential late-life mediators (e.g., disease multimorbidity\textsuperscript{17}). Fifth, dementia is also not a single disease and future, adequately-powered studies with dementia subtypes should test for DunedinPACE’s specificity. Sixth, ample evidence points to genetic loci contributing to dementias\textsuperscript{49}. In contrast, DNA-methylation variation represents epigenetic results of processes along pathways toward dementia, suggesting DunedinPACE is best considered a non-causal risk indicator.

As the search gains steam for geroscience-guided interventions that might slow aging and prevent the onset of age-related diseases, including Alzheimer’s disease and related dementias, the need for reliable measures of biological aging related to dementia is becoming more apparent. Such measures could serve to identify people at high risk for future dementia, and could serve as surrogate measures to evaluate interventions while waiting for the longer-term outcome of dementia. DNA-methylation measures of aging have offered promise, but their relation to cognitive aging and dementia has been equivocal. Here we find evidence that a third generation DNA-methylation measure of aging, trained on longitudinally measured biological decline, may prove useful in dementia research.

**Acknowledgements**

We thank the Northern California Institute for Research and Education, the Alzheimer’s Therapeutic Research Institute at the University of Southern California and the Laboratory for Neuro Imaging at the University of Southern California for curation, coordination, and dissemination of ADNI data. The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University.
(Contract No. N01-HC-25195, HHSN268201500001I and 75N92019D00031). Funding support for the Framingham Dementia Survival Information for All Cohorts dataset was provided by NIA grant R01-AG054076. This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI.

Supplemental Tables and Figures --http://links.lww.com/WNL/C174

WNL-2022-200865_coinvestigator_appendix --
http://links.lww.com/WNL/C175

References


47. Nwanaji-Enwerem JC, Nwanaji-Enwerem U, Van Der Laan L, Galazka JM, Redeker NS, Cardenas A. A Longitudinal Epigenetic Aging and Leukocyte Analysis of Simulated Space
DOI:10.1016/j.celrep.2020.108406.


Tables

Table 1: Demographic and clinical characteristics of the ADNI and Framingham Heart Study Offspring cohorts. Values indicate mean(SD) unless otherwise indicated. *incident dementia (%).

<table>
<thead>
<tr>
<th></th>
<th>ADNI Individuals</th>
<th>ADNI all available samples</th>
<th>FHS Offspring Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>649</td>
<td>1,706</td>
<td>2,264</td>
</tr>
<tr>
<td>age, years (SD)</td>
<td>74.77(7.66)</td>
<td>75.44(7.66)</td>
<td>66.05 (8.88)</td>
</tr>
<tr>
<td>sex, % male</td>
<td>55.62</td>
<td>55.28</td>
<td>46.0</td>
</tr>
<tr>
<td>education, years (SD)</td>
<td>16.22(2.71)</td>
<td>16.21(2.70)</td>
<td>14.32 (2.60)</td>
</tr>
<tr>
<td>white (%)</td>
<td>98.00</td>
<td>98.00</td>
<td>98.50</td>
</tr>
<tr>
<td>dementia (%)</td>
<td>14.48</td>
<td>19.93</td>
<td>6.67*</td>
</tr>
</tbody>
</table>
Table 2: Descriptive data of the 1st generation (Horvath and Hannum), 2nd generation (PhenoAge and GrimAge) and 3rd generation (DunedinPACE) DNA methylation measures in ADNI. The Horvath, Hannum, PhenoAge, and GrimAge clocks are measured in units of chronological years, and DunedinPACE is measured in years of physiological decline per 1 chronological year. The third column reports the mean difference between males and females and the fourth column reports correlations (95% Confidence Intervals, adjusted for clustered data) between native DNA methylation aging measures (i.e. un-residualised for age) and chronological age (Pearson’s r);: The fifth column reports correlations (95% Confidence Intervals, adjusted for clustered data) between Age Advancement measures (i.e. residualised for age) and chronological age (Pearson’s r); *** p<.001

<table>
<thead>
<tr>
<th>Mean(SD)</th>
<th>Range</th>
<th>mean difference, males-females</th>
<th>Correlation (r) with Age (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Native measure</td>
<td>Age-Advancement measure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronological Age (Years)</td>
<td>75.44(7.66)</td>
<td>55.00-95.62</td>
<td>1.51</td>
</tr>
<tr>
<td>1st Generation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horvath</td>
<td>64.24(9.36)</td>
<td>28.41-111.74</td>
<td>3.18</td>
</tr>
<tr>
<td>Hannum</td>
<td>66.11(7.95)</td>
<td>44.78-99.36</td>
<td>2.69</td>
</tr>
<tr>
<td>2nd Generation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhenoAge</td>
<td>63.53(10.31)</td>
<td>32.07-118.80</td>
<td>2.80</td>
</tr>
<tr>
<td>GrimAge</td>
<td>76.00(7.46)</td>
<td>55.62-102.85</td>
<td>3.87</td>
</tr>
<tr>
<td>3rd Generation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DunedinPACE</td>
<td>1.00(0.12)</td>
<td>0.55-1.59</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Table 3: Associations between DNA methylation measures of aging and cognitive screening tests and function tests in ADNI. Panel A shows the results of linear regressions of cognitive screening scores (ADAS-Cog-13, higher scores=poorer performance; MMSE, lower scores=poorer performance; MoCA, lower scores=poorer performance) on the five DNA methylation measures of aging. Panel B shows the results of linear regressions of cognitive screening scores (RAVLT immediate recall, lower scores=poorer performance; RAVLT
percent forgotten, higher scores=poorer performance; Logical Memory, lower scores=poorer performance; Trail Making Test Part B, higher scores=poorer performance) on the five DNA methylation measures of aging. Both cognitive screening and function scores and DNA methylation measures were standardized to mean=0, SD=1 prior to analysis. All analyses included sex as a covariate in the model. To account for clustering, we report Huber-White robust standard errors. *** p<.001; ** p<.01

### Panel A: Screening Tests

<table>
<thead>
<tr>
<th>DNA methylation measures of aging</th>
<th>ADAS-Cog-13</th>
<th>MMSE</th>
<th>MoCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horvath</td>
<td>0.00(0.04)</td>
<td>0.01(0.03)</td>
<td>0.03(0.03)</td>
</tr>
<tr>
<td>Hannum</td>
<td>0.02(0.04)</td>
<td>-0.02(0.04)</td>
<td>-0.02(0.03)</td>
</tr>
<tr>
<td>PhenoAge</td>
<td>0.07(0.03)*</td>
<td>-0.06(0.03)</td>
<td>-0.07(0.03)*</td>
</tr>
<tr>
<td>GrimAge</td>
<td>0.01(0.03)</td>
<td>0.01(0.03)</td>
<td>-0.03(0.03)</td>
</tr>
<tr>
<td>DunedinPACE</td>
<td>0.08(0.04)*</td>
<td>-0.08(0.03)*</td>
<td>-0.10(0.04)**</td>
</tr>
</tbody>
</table>

### Panel B: Cognitive Function Tests

<table>
<thead>
<tr>
<th>DNA methylation measures of aging</th>
<th>RAVLT immediate recall</th>
<th>RAVLT percent forgotten</th>
<th>Logical Memory</th>
<th>Trail Making Test Part B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horvath</td>
<td>0.01(0.04)</td>
<td>0.01(0.03)</td>
<td>-0.01(0.04)</td>
<td>-0.02(0.03)</td>
</tr>
<tr>
<td>Hannum</td>
<td>-0.02(0.04)</td>
<td>0.00(0.03)</td>
<td>-0.01(0.04)</td>
<td>0.00(0.03)</td>
</tr>
<tr>
<td>PhenoAge</td>
<td>-0.06(0.04)</td>
<td>0.06(0.03)</td>
<td>-0.10(0.04)**</td>
<td>0.03(0.03)</td>
</tr>
<tr>
<td>GrimAge</td>
<td>-0.05(0.03)</td>
<td>0.03(0.03)</td>
<td>-0.03(0.03)</td>
<td>0.00(0.03)</td>
</tr>
<tr>
<td>DunedinPACE</td>
<td>-0.12(0.04)***</td>
<td>0.10(0.03)**</td>
<td>-0.11(0.04)**</td>
<td>0.06(0.04)</td>
</tr>
</tbody>
</table>
Table 4: Longitudinal associations of DNA methylation measures of aging with dementia in the Framingham Heart Study Cohort. The table reports effect-sizes for DNA methylation measures of aging from time-to-event analysis of dementia. The first panel shows results from a model including sex and age as covariates and the second panel shows results from a model that includes these covariates in addition to white blood cell abundance estimated from the DNA methylation data. Time-to-event model effect-sizes are reported as hazard ratios (HR) per standard deviation increase in the aging measures. *** p<.001; ** p<.01; * p<.05

<table>
<thead>
<tr>
<th>DNA methylation measures of aging</th>
<th>Model Adjusted for Sex</th>
<th></th>
<th></th>
<th>Model Adjusted for Sex and Estimated Cell Counts</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
<td>HR</td>
<td>95% CI</td>
<td></td>
</tr>
<tr>
<td>Horvath</td>
<td>1.18**</td>
<td>[1.06-1.32]</td>
<td>1.21**</td>
<td>[1.08-1.36]</td>
<td></td>
</tr>
<tr>
<td>Hannum</td>
<td>1.09</td>
<td>[0.96-1.23]</td>
<td>0.96</td>
<td>[0.83-1.12]</td>
<td></td>
</tr>
<tr>
<td>PhenoAge</td>
<td>1.25**</td>
<td>[1.08-1.44]</td>
<td>1.15</td>
<td>[0.98-1.36]</td>
<td></td>
</tr>
<tr>
<td>GrimAge</td>
<td>1.24**</td>
<td>[1.07-1.44]</td>
<td>1.05</td>
<td>[0.86-1.27]</td>
<td></td>
</tr>
<tr>
<td>DunedinPACE</td>
<td>1.39***</td>
<td>[1.21-1.61]</td>
<td>1.27**</td>
<td>[1.07-1.49]</td>
<td></td>
</tr>
</tbody>
</table>
Figure Captions

Figure 1: Correlations between the five DNA methylation measures of aging in ADNI. The matrix above the diagonal plots the Pearson $r$ statistic (with cell color depicting magnitude from light=low to dark=high), while the matrix below the diagonal shows the scatterplots for each comparison. The dotted red line describes the linear regression line. Correlations are adjusted for sex.
Figure 2: Mean DNA methylation age advancement values in ADNI within each of the three diagnostic categories. Values are grouped by diagnostic category at time of interview; Cognitively Normal (CN, blue bars), Mild Cognitive Impairment (MCI, gold bars) and Dementia (grey bars). The three diagnostic status groups did not differ significantly from one another on either of the first-generation DNA methylation clocks (Horvath and Hannum clocks) or on the second-generation clocks (PhenoAge and GrimAge). In contrast, individuals with MCI or Dementia had faster DunedinPACE scores than those who were Cognitively Normal. Bars represent means and whiskers represent 95% Confidence Intervals. Values are standardized to mean=0, SD=1.
Figure 3: DunedinPACE values by test-score quintile for the Rey Auditory Verbal Learning test, Logical memory test, and Trail Making test cognitive assessments in ADNI. Faster DunedinPACE was associated with poorer learning and memory (RAVLT, immediate recall (A) and percent forgotten (B)), episodic memory (Logical memory test (C)), and executive functioning (trail-making test part B (D)). Cognitive function scores (x-axis) are binned into quintiles (1-5); grey dots represent mean age-advancement value and whiskers represent 95% Confidence Intervals. The y-axis represents DunedinPACE (age-residualized, adjusted for sex, and standardized to mean=0, SD=1).
Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia
Neurology published online July 6, 2022
DOI 10.1212/WNL.0000000000200898

This information is current as of July 6, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2022/07/06/WNL.0000000000200898.full

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Cognitive Disorders/Dementia
http://n.neurology.org/cgi/collection/all_cognitive_disorders_dementia
Cognitive aging
http://n.neurology.org/cgi/collection/cognitive_aging

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise